Drugs / TQB2930
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05380882 | May 2022 → Apr 2023 | cancer of unknown primary site | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT07653685 | Sep 2026 → Jun 2027 expected | colorectal cancer | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07512583 | May 2026 → Mar 2028 expected | neoplasm | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06202261 | Apr 2023 → Dec 2026 expected | breast carcinoma | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07047365 | Jul 2025 → Jun 2028 expected | HER2 positive breast carcinoma | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-06-04 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Results 2国、22城、500+专家！“全球肿瘤进展巅峰对话”中美连线直播 谢承润：国产创新药已处国际前沿 冀“中国方案”成为“世界方案” cttq.com ↗
研究表明其对于既往使用多种HER2靶向药物治疗失败的患者，客观缓解达到48.1%，6个月PFS率为71%； |
| 2025-05-24 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Results “国药之光”领衔12大ORAL刷屏ASCO，中国生物制药引领中国创新药企冲刺全球新 cttq.com ↗
本研究纳入55例至少2线抗HER2药物治疗失败的HER2阳性乳腺癌患者，总体ORR为48.1%，较HER2 TKI和HER2单抗等治疗方案存在显著提升；mPFS尚未达到，6个月PFS率为71%；mOS尚未成熟，预期有望超过2年。 |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-06-04 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2国、22城、500+专家！“全球肿瘤进展巅峰对话”中美连线直播 谢承润：国产创新药已处国际前沿 冀“中国方案”成为“世界方案” cttq.com ↗ |
| 2025-05-24 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | “国药之光”领衔12大ORAL刷屏ASCO，中国生物制药引领中国创新药企冲刺全球新 cttq.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TQB2930 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06202261 ↗ |
| Action | Inhibit | “leading to a dual HER2 signal blockage” NCT05380882 ↗ |
| Route | Intravenous | “intravenous infusion of TQB2930 injection” NCT05380882 ↗ |